BMCM
RPRX icon

Bryn Mawr Capital Management’s Royalty Pharma RPRX Stock Holding History

Bryn Mawr Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Sell
305,786
-663
-0.2% -$34.5K 0.75% 34
2026
Q1 		$14.7M Sell
306,449
-3,360
-1% -$147K 0.71% 34
2025
Q4 		$12M Sell
309,809
-1,981
-0.6% -$75.5K 0.58% 49
2025
Q3 		$11M Buy
311,790
+11,664
+4% +$422K 0.55% 51
2025
Q2 		$10.8M Buy
300,126
+10,353
+4% +$343K 0.59% 46
2025
Q1 		$9.02M Buy
289,773
+280,673
+3,084% +$8.9M 0.54% 53
2024
Q4 		$232K Buy
9,100
+600
+7% +$15.9K 0.01% 383
2024
Q3 		$240K Buy
+8,500
New +$235K 0.01% 369

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bryn Mawr Capital Management's RPRX Position: Q2 2026 in Review

Bryn Mawr Capital Management reduced its Royalty Pharma (RPRX) stake by 0.22% in Q2 2026, selling an estimated $34.5K and leaving 305,786 shares worth $17.1M. The position accounts for 0.75% of the portfolio, ranked #34.

Bryn Mawr Capital Management first reported a position in RPRX in Q3 2024 and has held it in 8 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Bryn Mawr Capital Management held 305,786 shares of Royalty Pharma worth $17.1M as of Q2 2026.
  • Bryn Mawr Capital Management sold 663 Royalty Pharma shares in Q2 2026, an estimated $34.5K.
  • Royalty Pharma made up 0.75% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #34 holding.
  • Bryn Mawr Capital Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 8 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.